CliffBio
small molecule

DAPSONE

DAPSONE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameDAPSONE
Active ingredientDAPSONE
Strength100MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2019
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.